Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Views - The market performance of the traditional Chinese medicine (TCM) sector has shown a modest increase of 2.89%, which is the smallest among the pharmaceutical sub-sectors due to a lack of short-term catalysts and market style shifts [4][5] - The TCM sector's price-to-earnings (PE) ratio (ttm) is 27.39X, reflecting a 0.76X increase from the previous week, while the price-to-book (PB) ratio (lf) stands at 2.3X, up 0.06X [6] - The national health conference held in January 2026 indicates a positive outlook for the penetration rate of TCM services, suggesting a comprehensive development approach for TCM in various healthcare aspects [8] Summary by Sections Market Performance - The TCM sector's performance is lagging behind other pharmaceutical sub-sectors, with a 12-month relative return of -24% compared to the CSI 300 index [4] - The TCM sector's index closed at 6414.65 points, with a weekly increase of 2.89% [21] Valuation - The TCM sector's PE ratio (ttm) is at 27.39X, with a maximum of 30.26X and a minimum of 24.72X over the past year [6] - The PB ratio (lf) is 2.3X, with a maximum of 2.52X and a minimum of 2.17X in the same period [6] Industry Trends - The TCM material market has seen a slight decline in price index due to reduced market traffic, with a total index of 227.06 points, down 0.6% week-on-week [7] - The national health conference emphasizes the ongoing development of TCM services, which is expected to enhance its integration into the healthcare system [8] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [9] - Specific investment targets include companies with strong R&D capabilities and unique products, as well as those less affected by centralized procurement [11]

（编辑 楚丽君） 证券日报网讯 1月9日，佐力药业在互动平台回答投资者提问时表示，股价波动受宏观环境及市场情绪 等多重因素综合影响，公司将持续做好经营，努力提升经营效益，切实维护好广大投资者权益和资本市 场稳定。 ...

Core Insights - In December 2025, a total of 713 private equity firms participated in A-share research activities, covering 392 stocks across 28 primary industries, with a total of 1,765 research instances recorded [1] - Notably, 43 large private equity firms conducted research on 151 A-shares, accounting for 16.49% of the total research instances [1] - The most researched stocks included Haiguang Information and Zhongke Shuguang, each receiving 117 research instances, significantly outpacing other A-shares [1][2] Industry Focus - The top ten stocks receiving the most attention from private equity firms were primarily in the machinery, electronics, and pharmaceutical industries, with three stocks from the machinery sector making the list [2][4] - The electronics industry had 60 stocks researched, totaling 384 instances, while the machinery sector had 64 stocks with 286 instances, making them the focal points of private equity research [4][5] - Other industries that garnered significant attention included computer, pharmaceutical, automotive, and power equipment, each surpassing 100 research instances [4][5] Stock Research Rankings - The top ten A-shares by research instances in December included: - Haiguang Information (117 instances) - Zhongke Shuguang (117 instances) - Changan Automobile (42 instances) - Jerry Holdings (34 instances) - Boying Welding (31 instances) - Weichuang Electric (30 instances) - Yipin Hong (30 instances) - Huqin Technology (27 instances) - Huatong Cable (25 instances) - Zoli Pharmaceutical (24 instances) [3] Active Private Equity Firms - In December, 24 private equity firms conducted at least 10 research instances, with 12 of them being large firms [5][6] - Zhengyuan Investment led with 28 research instances covering 27 stocks, primarily in the machinery sector [6][7] - Other notable firms included Dui Shui Quan with 25 instances, Gao Yi Asset and He Xie Hui Yi Asset with 21 instances each, and Panjing Investment with 19 instances [6][7][8]

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the sector [5]. Core Insights - The market performance for the Chinese medicine sector showed a slight decline of 1.67% last week, which is relatively smaller compared to other pharmaceutical segments [1]. - The price-to-earnings (PE) ratio for the Chinese medicine sector is reported at 26.63X, with a slight decrease of 0.45X week-on-week, indicating a valuation within the historical range [2]. - The demand for tonic herbs continues to grow, leading to a slight increase in the Chinese medicinal herb price index, which rose by 0.1% last week [3]. - The integration of Chinese medicinal pieces into a national drug traceability code system is accelerating, which is expected to enhance the quality and management of the industry [4]. Summary by Sections Market Performance - The Chinese medicine sector index closed at 6234.32 points, down 1.67% last week, while the overall pharmaceutical sector index fell by 2.06% [1][11]. - Notable companies with strong performance include Wanbangde, Tianmu Pharmaceutical, and Guhang Medicine, while underperformers include *ST Changyao and ST Hulahua [1][17]. Valuation - The current PE ratio for the Chinese medicine sector is 26.63X, with a year-to-date maximum of 30.26X and a minimum of 24.72X [2]. - The price-to-book (PB) ratio stands at 2.24X, with a year-to-date maximum of 2.52X and a minimum of 2.17X [2]. Industry Trends - The demand for tonic herbs is on the rise, contributing to a slight increase in the price index for Chinese medicinal herbs [3]. - The national drug traceability system for Chinese medicinal pieces is being implemented, which is expected to improve the quality and traceability of medicinal materials [4]. Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [5]. - Specific investment targets include companies with strong R&D capabilities, unique products, and those less affected by price reductions due to centralized procurement [9].

Market Overview - The Chinese medicine sector experienced a decline of 0.3% on December 31, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3968.84, up 0.09%, while the Shenzhen Component Index closed at 13525.02, down 0.58% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - ST Ziling: closed at 4.35, up 2.84% with a trading volume of 476,800 shares and a turnover of 207 million yuan [1] - Guohan Pharmaceutical: closed at 11.21, up 2.66% with a trading volume of 48,400 shares and a turnover of 54.01 million yuan [1] - Major decliners included: - *ST Changyao: closed at 0.87, down 8.42% with a trading volume of 828,300 shares and a turnover of 73.23 million yuan [2] - ST Huluwa: closed at 7.62, down 4.63% with a trading volume of 176,200 shares and a turnover of 134 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 399 million yuan from institutional investors, while retail investors contributed a net inflow of 376 million yuan [2] - The sector's capital flow details indicate: - Dong'e Ejiao had a net inflow of 27.6 million yuan from institutional investors, but a net outflow of 14.69 million yuan from speculative funds [3] - Guohan Pharmaceutical experienced a net inflow of 8.03 million yuan from institutional investors, but a net outflow of 9.69 million yuan from retail investors [3]

证券代码：300181 证券简称：佐力药业 公告编号：2025-071 浙江佐力药业股份有限公司 关于参与竞拍土地使用权的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、交易概述 浙江佐力药业股份有限公司（以下简称"公司"）于2025年12月2日召开第八 届董事会第十次（临时）会议，审议通过了《关于参与竞拍土地使用权的议案》。 为满足公司未来发展需要，同意公司拟使用自有资金不超过6,500万元参与土地 使用权竞拍，并授权公司管理层负责办理本次土地使用权竞拍、后续土地购买相 关手续及签署全部相关文件。 本次交易不构成关联交易，也不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。本次参与竞拍土地使用权事项在董事会审批权限内，无需提 交公司股东会审议批准。具体内容详见公司于2025年12月3日在巨潮资讯网披露 的《关于参与竞拍土地使用权的公告》（公告编号：2025-066）。 二、土地竞拍情况进展 近日，公司已竞得本次参与竞拍的阜溪街道G2024-041-2地块土地使用权， 并与德清县自然资源和规划局签订了《国有建设用地使用权出让合同》。现将 ...

Group 1 - On December 29, Zhaoli Pharmaceutical experienced a decline of 2.21% with a transaction volume of 269 million yuan. The financing buy amount for the day was 51.81 million yuan, while the financing repayment was 28.78 million yuan, resulting in a net financing buy of 23.03 million yuan. As of December 29, the total financing and securities lending balance was 586 million yuan [1] - The financing balance of Zhaoli Pharmaceutical on December 29 was 584 million yuan, accounting for 5.08% of the circulating market value, which is above the 70th percentile level over the past year, indicating a high position [1] - On the same day, Zhaoli Pharmaceutical repaid 800 shares in securities lending and sold 18,300 shares, with a selling amount of 300,100 yuan. The remaining securities lending volume was 133,700 shares, with a balance of 2.19 million yuan, exceeding the 90th percentile level over the past year, also indicating a high position [1] Group 2 - As of September 30, Zhaoli Pharmaceutical had 41,400 shareholders, an increase of 7.31% compared to the previous period. The average circulating shares per person decreased by 6.82% to 14,562 shares [2] - For the period from January to September 2025, Zhaoli Pharmaceutical achieved an operating income of 2.28 billion yuan, representing a year-on-year growth of 11.48%. The net profit attributable to the parent company was 510 million yuan, with a year-on-year increase of 21.00% [2] - Since its A-share listing, Zhaoli Pharmaceutical has distributed a total of 1.442 billion yuan in dividends, with 942 million yuan distributed in the last three years [3]

Core Insights - 2025 marks a pivotal year for China's innovative pharmaceuticals, with a significant increase in international collaborations and licensing agreements, indicating a shift from a pharmaceutical giant to a stronghold in the industry [1][3] - The total amount of outbound licensing agreements exceeded $100 billion, with upfront payments reaching $8.1 billion, showcasing a transition to multi-layered cooperation models [1][3] - China's biopharmaceutical market remains the second largest globally, with innovative drugs accounting for approximately 30% of global research, reflecting a critical leap from following to competing on a global scale [1][3] Internationalization - The internationalization of China's pharmaceutical industry saw explosive growth in 2025, highlighted by a surge in business development (BD) transactions and the popularity of "A+H" listings [3][4] - The total amount of outbound licensing for innovative drugs reached over $100 billion, a 75% increase from 2024, indicating a shift from merely selling products to actively engaging in global markets [3][4] - Notable BD transactions include significant agreements between major Chinese pharmaceutical companies and international firms, such as a $12.5 billion deal between Hengrui Medicine and GSK [3][4] Innovation - In 2025, advancements in cutting-edge technologies such as antibody-drug conjugates (ADC) and dual antibodies have shown promising results in cancer treatment [7][8] - The third-generation ADC technology has become mainstream, with significant efficacy demonstrated in treating solid tumors [7] - The dual antibody sector continues to lead, with Chinese companies achieving remarkable results in clinical trials, such as a 91% improvement in progression-free survival compared to existing treatments [8] Policy Support - The policy support for innovative drugs in China has reached unprecedented levels, with a notable increase in the number of approved innovative drugs [10][11] - The National Medical Products Administration approved 69 innovative drugs in 2025, a 44% increase from the previous year, covering various therapeutic areas [10] - The payment system for innovative drugs has been significantly upgraded, enhancing accessibility and affordability for patients [10][11] Mergers and Acquisitions - The pharmaceutical sector has seen a surge in mergers and acquisitions, with over 400 transactions announced globally, totaling approximately $111 billion, marking a 50% increase from 2024 [13][14] - Domestic mergers also showed strong activity, with significant deals indicating a shift towards quality improvement and resource consolidation among leading companies [13][14] - The trend reflects a transition from scale expansion to enhancing quality and efficiency, with companies focusing on high-value clinical pipelines [14]

Core Viewpoint - Zhaoli Pharmaceutical has established a strong brand influence in the traditional Chinese medicine (TCM) decoction pieces business, primarily focusing on the domestic market in Zhejiang province, with stable overall business performance [1] Group 1: Business Overview - The company has been deepening its market presence in Zhejiang, particularly in Hangzhou and Huzhou, leading to an increase in hospital coverage [1] - The overall business of TCM decoction pieces remains stable due to years of market cultivation [1] Group 2: Impact of Price Reduction - The recent centralized procurement led by Shandong province resulted in significant price reductions, which have influenced the market pricing landscape [1] - However, the company's primary focus on the domestic market means that the direct impact of centralized procurement on its business is limited [1]

Core Viewpoint - Zhaoli Pharmaceutical (300181) is in the research optimization and commercialization phase for its health products, with a planned official launch next year, contingent on R&D progress and sales channel development [1] Group 1 - The health products will primarily utilize internet sales and will operate separately from the existing pharmaceutical sales team [1] - The company aims to leverage its unique advantage in the exclusive raw material of Wuling mushroom powder to actively explore the market [1]